Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew W Roberts

Showing results (91-100 of 198) with videos related to

Pageof 20
Sort By:
The Journal of Antimicrobial Chemotherapy|October 24, 2025
Antifungal prophylaxis in patients with FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD)-positive acute myeloid leukaemia receiving sorafenib during initial induction and consolidation treatment in ALLG AMLM16 trialChin Fen Neoh, Michelle K Yong, Leesa Rowley, et al.
British Journal of Haematology|July 20, 2024
Potential impact of NOTCH1 activation on venetoclax sensitivity in chronic lymphocytic Leukaemia: In vitro insights and clinical implicationsMing-Yuan Gao, Angela Georgiou, Victor S Lin, et al.
Stem Cells (Dayton, Ohio)|August 27, 2005
Absence of suppressor of cytokine signalling 3 reduces self-renewal and promotes differentiation in murine embryonic stem cellsAriel Forrai, Kristy Boyle, Adam H Hart, et al.
Blood|February 8, 2006
More on Myb in myelofibrosis: molecular analyses of MYB and EP300 in 55 patients with myeloproliferative disordersDavid P Steensma, Animesh Pardanani, William S Stevenson, et al.
Blood|October 1, 2008
A key role for G-CSF-induced neutrophil production and trafficking during inflammatory arthritisJo L Eyles, Michael J Hickey, M Ursula Norman, et al.
Blood Reviews|March 25, 2020
Targeting MCL-1 in hematologic malignancies: Rationale and progressAndrew H Wei, Andrew W Roberts, Andrew Spencer, et al.
Hemasphere|December 31, 2025
Retreatment with venetoclax and rituximab following disease progression while off therapy in patients with chronic lymphocytic leukemiaDanielle M Brander, Andrew W Roberts, Thomas J Kipps, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 17, 2009
Clinical and immunohistochemical features associated with a response to bortezomib in patients with multiple myelomaMark A Dawson, Stephen S Opat, Yamna Taouk, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 17, 2010
Neutrophils require SHP1 to regulate IL-1β production and prevent inflammatory skin diseaseBen A Croker, Rowena S Lewis, Jeff J Babon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 26, 2018
Revised Dose Ramp-Up to Mitigate the Risk of Tumor Lysis Syndrome When Initiating Venetoclax in Patients With Mantle Cell LymphomaMatthew S Davids, Gottfried von Keudell, Craig A Portell, et al.
Pageof 20

Showing results (91-100 of 198) with videos related to

Sort By:
Pageof 20
The Journal of Antimicrobial Chemotherapy|October 24, 2025
Antifungal prophylaxis in patients with FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD)-positive acute myeloid leukaemia receiving sorafenib during initial induction and consolidation treatment in ALLG AMLM16 trialChin Fen Neoh, Michelle K Yong, Leesa Rowley, et al.
British Journal of Haematology|July 20, 2024
Potential impact of NOTCH1 activation on venetoclax sensitivity in chronic lymphocytic Leukaemia: In vitro insights and clinical implicationsMing-Yuan Gao, Angela Georgiou, Victor S Lin, et al.
Stem Cells (Dayton, Ohio)|August 27, 2005
Absence of suppressor of cytokine signalling 3 reduces self-renewal and promotes differentiation in murine embryonic stem cellsAriel Forrai, Kristy Boyle, Adam H Hart, et al.
Blood|February 8, 2006
More on Myb in myelofibrosis: molecular analyses of MYB and EP300 in 55 patients with myeloproliferative disordersDavid P Steensma, Animesh Pardanani, William S Stevenson, et al.
Blood|October 1, 2008
A key role for G-CSF-induced neutrophil production and trafficking during inflammatory arthritisJo L Eyles, Michael J Hickey, M Ursula Norman, et al.
Blood Reviews|March 25, 2020
Targeting MCL-1 in hematologic malignancies: Rationale and progressAndrew H Wei, Andrew W Roberts, Andrew Spencer, et al.
Hemasphere|December 31, 2025
Retreatment with venetoclax and rituximab following disease progression while off therapy in patients with chronic lymphocytic leukemiaDanielle M Brander, Andrew W Roberts, Thomas J Kipps, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 17, 2009
Clinical and immunohistochemical features associated with a response to bortezomib in patients with multiple myelomaMark A Dawson, Stephen S Opat, Yamna Taouk, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 17, 2010
Neutrophils require SHP1 to regulate IL-1β production and prevent inflammatory skin diseaseBen A Croker, Rowena S Lewis, Jeff J Babon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 26, 2018
Revised Dose Ramp-Up to Mitigate the Risk of Tumor Lysis Syndrome When Initiating Venetoclax in Patients With Mantle Cell LymphomaMatthew S Davids, Gottfried von Keudell, Craig A Portell, et al.
Pageof 20